Some doctors called it “an unethical political fix”. The
Cancer Drugs Fund, was set up at the prime minister’s behest to bring
last-chance drugs to dying patients, and it is expected to have its soaring
costs severely cut by an NHS England review. Pharmaceutical companies have
already expressed outrage because their drugs will no longer be bought through
the fund and have warned that thousands of terminally ill cancer patients will
lose crucial palliative care. New cancer drugs can add months to patients’
lives, but can cost £90,000 a course.
Many health experts say that the reining in of the fund –
set up to promote expensive cancer medicines in priority to drugs for all other
diseases – reveals its creation was merely a politically expedient move aimed
at ending the embarrassment of tabloid tales about cancer patients being denied
“life-saving” drugs. They want the CDF to be axed.
Professor Richard Sullivan, director of the Institute of
Cancer Policy, London, explained: “You cannot give priority to cancer over all
other serious illnesses, including coronary ailments and dementia. These types
of patients are just as deserving of expensive medicines as are cancer
patients.”
Health economist Professor Karl Claxton, of York University
said, “Last year the Cancer Drugs Fund spent £280m on medicines. That money did
some good but it would have done a lot more if it had been spent elsewhere in
the National Health Service.” According to Claxton, 21,645 quality adjusted
years of life – a measure of health improvement that is provided by a medicine
– would have been added to patients’ lives if that £280m had been used by the
NHS on all illnesses. By restricting this money to cancer fund patients, fewer
than 5,600 quality adjusted years of life were added to lives. “Quite frankly,
this has been an appalling, unfair use of NHS resources,” Claxton added.
Mangesh Thorat, a cancer surgeon at Queen Mary’s Hospital
London pointed out, “It is very hard to tell a patient there is a drug that
could add several months to their lives but that we cannot afford to give it to
them. On the other hand, in saying that cancer cases deserve exemptions from
cost controls – while other diseases are not permitted these exemptions – is
basic discrimination. You are saying that one type of disease is more important
than any other type. In fact, the problem of high-cost drugs is always going to
be with us. The Cancer Drugs Fund is completely the wrong answer to the issue.”
The Cancer Drugs Fund was robustly defended by the lobby
group which represents drug supply companies, the Association of the British
Pharmaceutical Industry. National Institute for Health and Care Excellence
(Nice) used to negotiate prices of new drugs with pharmaceutical firms and
would eventually give approval after those companies agreed to lower their
prices. The Cancer Drugs Fund allowed the companies to continue to demand top
prices. As a result, its budget soared. “That’s why the fund is now trouble,”
Sullivan added.
The pharmaceutical companies will insist that the gross
inflation between cost and sale price is to cover the huge expenditure that
goes into the complete lifecycle of creating the drug - discovery, research,
testing and so on. What they aren't so quick to admit is that this includes
their own advertising campaigns - which may run up to a third of the total
cost. They advertise to increase their profits, not to research new treatments,
yet we pay for their advertising budget under the guise of "total cost of
development". CDF may indeed a waste of NHS cash. But this is minutiae to
the larger problem. Pharmaceutical companies who think they're untouchable,
mostly because governments like ours treat them as though they are. Pharmaceutical
companies will charge what the market will bear, which is usually the maximum,
when faced with cancer. How many times have we been told that a drug can't be
supplied on the NHS because it's prohibitively expensive? Compare that to how
many times we've been told that a drug can't be provided on the NHS because the
manufacturer has imposed an unrealistic, unsustainable and exploitative price.
Incredibly, everything about capitalism is about competition
– even life itself. It seems that the ruling class is not content with causing
hostility between ordinary working people not receiving benefits and those who
do, those in low paid jobs and those who are not in paid employment, those who
are born in the UK and those who aren't and those in the public sector and
those in the private sector. Now the ruling elite are causing hostility between
those with one serious, life threatening illness and those with a different
serious, life threatening illness.
We need to stop this pathetic in-fighting and target the root
of the problem - capitalism
An update
ReplyDeletehttp://www.theguardian.com/society/2015/jan/12/camcer-drugs-fund-financial-boost-but-cut-treatments-nhs
Dr Charlotte Chamberlain, clinical research fellow at the School of Social and Community Medicine, University of Bristol, said: “The CDF has been seen as a ‘back door’ to funding high-cost cancer drugs on the NHS. Introducing negotiations with pharmaceutical companies over cost is overdue to prevent further unsustainable costs for the NHS.”